Peptide drugs plan advanced by Trump administration, RFK Jr.

Key Points:

• U.S. health officials, under Health Secretary Robert F. Kennedy Jr., are advancing a plan to allow specialty pharmacies to produce certain peptides, which are largely unregulated injections popular among wellness influencers.
• The Department of Health and Human Services submitted an interim access policy on peptides to the White House, with the Office of Management and Budget reviewing the plan for economic impact.
• Peptides like BPC-157, promoted for muscle building and healing but not approved by the FDA, could be temporarily compounded by pharmacies under this policy, bypassing previous FDA restrictions due to safety concerns.
• The move aligns with Kennedy's efforts to ease access to wellness products popular in the Make America Healthy Again movement, despite FDA scientists warning that these peptides lack sufficient safety and efficacy data.
• The policy would use enforcement discretion to allow compounding pharmacies to produce certain peptides without formal FDA approval, avoiding the lengthy federal rulemaking process.